2. Search Result
Search Result
Results for "

BH4

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

2

Peptides

2

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0124A
    Sapropterin dihydrochloride
    1 Publications Verification

    (6R)-BH4 dihydrochloride; (6R)-Tetrahydro-L-biopterin dihydrochloride

    		 Others Metabolic Disease Inflammation/Immunology
    Sapropterin ((6R)-BH4) is an orally active phenylalanine hydroxylase (PAH) cofactor, which is effective in reducing blood phenylalanine concentrations. Sapropterin also drives autoimmunity. Sapropterin can be used in study of phenylketonuria (PKU) .
    Sapropterin dihydrochloride
  • HY-100954
    2,4-Diamino-6-hydroxypyrimidine
    1 Publications Verification

    		 NO Synthase Inflammation/Immunology
    2,4-Diamino-6-hydroxypyrimidine is a specific GTP cyclohydrolase I inhibitor (the rate-limiting enzyme in de novo pterin synthesis). 2,4-Diamino-6-hydroxypyrimidine blocks Tetrahydrobiopterin (BH4) synthesis and suppresses NO production .
    2,4-Diamino-6-hydroxypyrimidine
  • HY-A0124AR
    Sapropterin (dihydrochloride) (Standard)

    		Others Metabolic Disease Inflammation/Immunology
    Sapropterin (dihydrochloride) (Standard) is the analytical standard of Sapropterin (dihydrochloride). This product is intended for research and analytical applications. Sapropterin ((6R)-BH4) is an orally active phenylalanine hydroxylase (PAH) cofactor, which is effective in reducing blood phenylalanine concentrations. Sapropterin also drives autoimmunity. Sapropterin can be used in study of phenylketonuria (PKU) .
    Sapropterin (dihydrochloride) (Standard)
  • HY-P5320
    TAT-BH4 (Bcl-xL)

    		Apoptosis Others
    TAT-BH4 (Bcl-xL) localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 can be used for research of diseases caused by accelerated apoptosis .
    TAT-BH4 (Bcl-xL)
  • HY-P5320A
    TAT-BH4 (Bcl-xL) (TFA)

    		Apoptosis Others
    TAT-BH4 (Bcl-xL) TFA is localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 TFA can be used for research of diseases caused by accelerated apoptosis .
    TAT-BH4 (Bcl-xL) (TFA)
  • HY-144856S1
    Sapropterin-d3

    (6R)-BH4-d3; (6R)-Tetrahydro-L-biopterin-d3

    		 Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Sapropterin-d3 ((6R)-BH4-d3) is deuterium labeled Sapropterin. Sapropterin ((6R)-BH4) is an orally active phenylalanine hydroxylase (PAH) cofactor, which is effective in reducing blood phenylalanine concentrations. Sapropterin can be used in study of phenylketonuria (PKU) .
    Sapropterin-d3
  • HY-A0124
    Sapropterin

    (6R)-BH4; (6R)-Tetrahydro-L-biopterin

    		 Endogenous Metabolite Metabolic Disease
    Sapropterin ((6R)-BH4) is an orally active phenylalanine hydroxylase (PAH) cofactor, which is effective in reducing blood phenylalanine concentrations. Sapropterin can be used in study of phenylketonuria (PKU) .
    Sapropterin
  • HY-101083
    BDA-366

    		Bcl-2 Family Cancer
    BDA-366 is a potent Bcl2 antagonist (Ki = 3.3 nM), binding Bcl2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells .
    BDA-366
  • HY-123020
    CYD-2-88

    BDA-366 analog

    		 Others Cancer
    CYD-2-88 (BDA-366 analog) is a BDA-366 (HY-101083) (Bcl2 BH4 antagonist) analog. CYD-2-88 (20 mg/kg, i.p.) inhibits tumor growth in NSCLC H460 xenografts mice .
    CYD-2-88
  • HY-101083A
    (Rac)-BDA-366

    		Bcl-2 Family Cancer
    (Rac)-BDA-366 (example 2) is the despinner of BDA-366 (HY-101083). BDA-366 is a potent Bcl-2 antagonist (Ki=3.3 nM), binding Bcl-2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl-2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells .
    (Rac)-BDA-366
  • HY-112234
    L-Sepiapterin

    Sepiapterin

    		 Endogenous Metabolite Cancer
    L-Sepiapterin (Sepiapterin) is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 S6K-dependent VEGFR-2 expression .
    L-Sepiapterin
  • HY-115510
    SPR inhibitor 3

    SPRi3

    		 Others Inflammation/Immunology
    SPR inhibitor 3 (SPRi3) is a potent sepiapterin reductase (SPR) inhibitor. SPR inhibitor 3 (SPRi3) displays high binding affinity to human SPR in a cell-free assay (IC50=74 nM) and efficiently reduces biopterin levels in a cell-based assay (IC50=5.2 μM). SPR inhibitor 3 (SPRi3) reduces neuropathic and inflammatory pain through a reduction of BH4 levels .
    SPR inhibitor 3
  • HY-W750595
    6-(L-1,2,3-Trihydroxybutyl)-pterin

    		Others Cancer
    6-(L-1,2,3-Trihydroxybutyl)-pterin is a derivative of L-biopterin (HY-102015) and is the oxidized form of tetrahydro-L-biopterin (BH4) as well as D-biopterin. Co-ingestion of 6-(L-1,2,3-Trihydroxybutyl)-pterin (0.5%) with the carcinogen 4-dimethylaminoazobenzene reduces the incidence of 4-dimethylaminoazobenzene-induced liver tumors in rats. 6-(L-1,2,3-Trihydroxybutyl)-pterin has been used as an internal standard for the LC-MS quantification of biopterin and neopterin in rat plasma.
    6-(L-1,2,3-Trihydroxybutyl)-pterin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: